{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T12:39:29Z","timestamp":1719319169410},"reference-count":129,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmic Epidemiology"],"published-print":{"date-parts":[[2020,9,2]]},"DOI":"10.1080\/09286586.2020.1792938","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T07:03:01Z","timestamp":1595314981000},"page":"325-338","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["A Systematic Review of Economic Studies Evaluating Ophthalmic Drugs: An Analysis of the Health-state Utilities"],"prefix":"10.1080","volume":"27","author":[{"given":"In\u00eas","family":"Ribeiro","sequence":"first","affiliation":[{"name":"AIBILI \u2013 Association for Innovation and Biomedical Research on Light and Image, CHAD \u2013 Centre for Health Technology Assessment and Drug Research, Coimbra, Portugal"},{"name":"Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal"}]},{"given":"Francisco","family":"Batel Marques","sequence":"additional","affiliation":[{"name":"AIBILI \u2013 Association for Innovation and Biomedical Research on Light and Image, CHAD \u2013 Centre for Health Technology Assessment and Drug Research, Coimbra, Portugal"},{"name":"Laboratory of Social Pharmacy and Public Health, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal"}]},{"given":"Diogo","family":"Mendes","sequence":"additional","affiliation":[{"name":"AIBILI \u2013 Association for Innovation and Biomedical Research on Light and Image, CHAD \u2013 Centre for Health Technology Assessment and Drug Research, Coimbra, Portugal"}]},{"given":"Carlos","family":"Alves","sequence":"additional","affiliation":[{"name":"AIBILI \u2013 Association for Innovation and Biomedical Research on Light and Image, CHAD \u2013 Centre for Health Technology Assessment and Drug Research, Coimbra, Portugal"},{"name":"Laboratory of Social Pharmacy and Public Health, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal"}]}],"member":"301","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"cit0001","first-page":"CD007419","volume":"6","author":"Virgili G","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0002","first-page":"CD007325","volume":"5","author":"Braithwaite T","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0003","first-page":"CD009510","volume":"1","author":"Mitry D","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0004","first-page":"CD005139","volume":"8","author":"Solomon SD","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1177\/2515841419870366"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-3225"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.09.025"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0145"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018289"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.02.015"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.10.036"},{"key":"cit0012","unstructured":"The National Institute for Health and Care Excellence. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. https:\/\/www.nice.org.uk\/guidance\/ta283\/chapter\/4-Consideration-of-the-evidence#cost-effectiveness. Published May 2013. Accessed October 7, 2019."},{"key":"cit0013","unstructured":"The National Institute for Health and Care Excellence. Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears. https:\/\/www.nice.org.uk\/guidance\/ta369\/chapter\/4-Consideration-of-the-evidence#summary-of-appraisal-committees-key-conclusions. Published December 2015. Accessed October 7, 2019."},{"key":"cit0014","unstructured":"The National Institute for Health and Care Excellence. Aflibercept for treating diabetic macular oedema. https:\/\/www.nice.org.uk\/guidance\/ta346\/chapter\/4-Consideration-of-the-evidence. Published July 2015. Accessed October 7, 2019."},{"key":"cit0015","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/. Published April 2013. Accessed April 24, 2019."},{"key":"cit0016","unstructured":"York Health Economics Consortium. Cost-utility analysis. https:\/\/www.yhec.co.uk\/glossary\/cost-utility-analysis\/. Published 2016. Accessed May 20, 2019."},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.06.001"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1387118"},{"key":"cit0019","first-page":"293","volume":"2016","author":"Hao Y","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2019.1579646"},{"key":"cit0021","unstructured":"National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. 2004. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/191504\/NICE_guide_to_the_methods_of_technology_appraisal.pdf. Published April 2004. Accessed May 20, 2019."},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1049"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197670"},{"key":"cit0025","unstructured":"Zorginstituut Nederland. Guideline for economic evaluations in healthcare. https:\/\/tools.ispor.org\/PEguidelines\/source\/Netherlands_Guideline_for_economic_evaluations_in_healthcare.pdf. Published 2016. Accessed July 16, 2019."},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.7.608"},{"key":"cit0027","unstructured":"Academy of Managed Care Pharmacy. The AMCP format for formulary submissions Version 4.0. http:\/\/www.amcp.org\/FormatV4\/. Published 2016. Accessed July 16, 2019."},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0459-z"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1245196"},{"key":"cit0030","unstructured":"Fukuda T. Guideline for . Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council. Version 1.0. https:\/\/tools.ispor.org\/PEguidelines\/source\/Japanese_PE_Guideline.pdf. Published 2016. Accessed July 16, 2019."},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0367-9"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12964"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13185"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.3310\/hta19780"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-014-0090-0"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005094"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-014-2641-3"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.10.037"},{"key":"cit0039","doi-asserted-by":"crossref","unstructured":"Academy of Managed Care Pharmacy. The AMCP format for formulary submissions Version 3.1. https:\/\/www.amcp.org\/sites\/default\/files\/2019-03\/Format%20Version%203.1%20Final%202.2013_0.pdf. Published 2012. Accessed July 16, 2019.","DOI":"10.18553\/jmcp.2010.16.S1-A.1"},{"key":"cit0040","first-page":"56","volume":"111","author":"Stein JD","year":"2013","journal-title":"Trans Am Ophthalmol Soc"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.01.005"},{"key":"cit0042","first-page":"29","volume":"4","author":"Nwanze CC","year":"2012","journal-title":"Clin Med Insights Ther"},{"key":"cit0043","unstructured":"Academy of Managed Care Pharmacy. The AMCP format for formulary submissions Version 3.0. https:\/\/www.amcp.org\/sites\/default\/files\/2019-03\/AMCP%20Format%20for%20Formulary%20Submissions%2C%20Version%203.0.pdf. Published 2009. Accessed July 16, 2019."},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.3310\/hta16060"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181babd8e"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-009-1156-9"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2009.07.011"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.3129\/i10-047"},{"key":"cit0049","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada 3rd edition. https:\/\/www.cadth.ca\/media\/pdf\/186_EconomicGuidelines_e.pdf. Published 2006. Accessed July 16, 2019."},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.07.010"},{"key":"cit0051","unstructured":"Institute for Quality and Efficiency in Health Care. General methods for the assessment of the relation of benefits to costs. https:\/\/tools.ispor.org\/PEguidelines\/source\/Germany_AssessmentoftheRelationofBenefitstoCosts_En.pdf. Published 2009. Accessed July 16, 2019."},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2010.01546.x"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.10.023"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.08.033"},{"key":"cit0055","unstructured":"Academy of Managed Care Pharmacy. The AMCP format for formulary submissions Version 2.1. https:\/\/www.amcp.org\/sites\/default\/files\/2019-03\/Format%20Version%202.1%20April%202005.pdf. Published 2005. Accessed July 16, 2019."},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.3310\/hta12160"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.07.018"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.12.025"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-6-12"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00283.x"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.09.019"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702636"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.09.001"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.116616"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725100-00005"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.04.061"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-4182(05)80079-1"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2003.039131"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2003.023986"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.3310\/hta7090"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00764-3"},{"key":"cit0072","unstructured":"Academy of Managed Care Pharmacy. Format for formulary submissions Version 1.0. https:\/\/www.amcp.org\/sites\/default\/files\/2019-03\/Format%20Version%201%200%20Final%2010.2000.pdf. Published 2000. Accessed July 16, 2019."},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3804-4"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-016-0056-1"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.1669"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.032"},{"key":"cit0077","first-page":"S63","volume":"21","author":"Moore PT","year":"2015","journal-title":"Am J Manag Care"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S82556"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-015-0045-z"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S44079"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02706.x"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2007.05.003"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X187865"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02318.x"},{"key":"cit0085","first-page":"812","volume":"9","author":"Stewart WC","year":"2009","journal-title":"Int J Ophthalmol (Guoki Yanke Zazhi)"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702964"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.3111\/200508065084"},{"key":"cit0088","unstructured":"Coll\u00e8ge des \u00c9conomistes de la Sant\u00e9. French guidelines for the economic evaluation of health care technologies. http:\/\/www.ces-asso.org\/docs\/France_Guidelines_HE_Evaluation.PDF. Published 2000. Accessed July 16, 2019."},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312756"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312765"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.3310\/hta21680"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.04.022"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0279-0"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.909435"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.12.034"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199813040-00008"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199709010-00003"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2008.608"},{"key":"cit0099","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/IEB.0b013e3181ac94fb","volume":"10","author":"Brown GC","year":"2009","journal-title":"Evidence-Based Ophthalmol"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-014-0216-y"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2018.05.022"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.09.2841"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.03.029"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1097\/00132578-200201000-00025"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.3109\/09286586.2014.895843"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.3109\/09286586.2014.888456"},{"key":"cit0107","unstructured":"Pharmaceutical Management Agency. Prescription for pharmacoeconomic analysis - methods for cost-utility analysis Version 2.2. https:\/\/www.pharmac.govt.nz\/assets\/pfpa-2-2.pdf. Published 2015. Accessed May 31, 2019."},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2015.1314"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2688"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.3109\/09286586.2014.885057"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-017-0748-z"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-25"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012732"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-12-43"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8992"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2012.137"},{"key":"cit0117","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada 4th edition. https:\/\/cadth.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf. Published March 2017. Accessed May 31, 2019."},{"key":"cit0118","unstructured":"Egyptian Drug Authority. Guidelines for reporting pharmacoeconomic evaluations. http:\/\/www.eda.mohp.gov.eg\/Files\/402_Egyptian_Pharmacoeconomic_guidelines.pdf. Published August 2013. Accessed May 31, 2019."},{"key":"cit0119","unstructured":"National Institute of Pharmacy and Nutrition. Professional healthcare guideline on the methodology of health technology assessment. https:\/\/tools.ispor.org\/PEguidelines\/source\/HTA_Guideline_HUN_eng.pdf. Published 2017. Accessed May 31, 2019."},{"key":"cit0120","unstructured":"Health Information and Quality Authority. Guidelines for the economic evaluation of health technologies in Ireland. https:\/\/tools.ispor.org\/PEguidelines\/source\/HIQA_Economic_Guidelines_2018.pdf. Published 2018. Accessed May 31, 2019."},{"key":"cit0121","first-page":"S43","volume":"91","author":"Sakthong P","year":"2008","journal-title":"J Med Assoc Thai"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00522.x"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.01.004"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-1389"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-10"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-009-9499-6"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.1.47"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00527.x"},{"key":"cit0129","doi-asserted-by":"publisher","DOI":"10.1002\/9781119959946.ch38"}],"container-title":["Ophthalmic Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09286586.2020.1792938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T23:51:24Z","timestamp":1620604284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09286586.2020.1792938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":129,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9,2]]}},"alternative-id":["10.1080\/09286586.2020.1792938"],"URL":"https:\/\/doi.org\/10.1080\/09286586.2020.1792938","relation":{},"ISSN":["0928-6586","1744-5086"],"issn-type":[{"value":"0928-6586","type":"print"},{"value":"1744-5086","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iope20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iope20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-11-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}